Table 7.

Zanubrutinib clinical studies in patients with CLL or SLL.

Clinical Study	Type of Study	Eligible Patients	Treatment	Endpoints	Conclusion	Ref.
SEQUOIA	Phase III, open-label, multicenter study	Previously untreated CLL or SLL ≥65 or ≥18 years ECOG 0 -2	Zanubrutinib vs. BR	PFS	Zanubrutinib showed a notable improvement in PFS and safety profile compared to BR accompanied. These results lend support to zanubrutinib as a potential treatment option for untreated CLL and SLL.	[128]
ALPINE	Head-to-head Phase III study	r/r CLL/SLL patients	Zanubrutinib vs. ibrutinib	ORR PFS OS	Zanubrutinib demonstrated superiority over ibrutinib in terms of PFS, OS, and safety profile. In patients with del17p, TP53mut, or both, those treated with zanubrutinib experienced PFS compared with ibrutinib.	[129]
NCT03206918	Phase II, single-arm, multicenter study	r/r CLL/SLL patients	Zanubrutinib	ORR PFS	Results showed that administering zanubrutinib twice daily led to a significant occurrence of lasting responses. Zanubrutinib presents the possibility of enhanced safety and tolerability compared to current treatment choices.	[130]